(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLD, CRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network!. Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Horizon Therapeutics' Daxdilimab Trial Falls Short on Primary Endpoint

  • July 23rd, 2023
  • 497 views

Horizon Therapeutics plc (Nasdaq: HZNP) reported disappointing results from its Phase 2 clinical trial for daxdilimab in the treatment of systemic lupus erythematosus (SLE), the most common type of lupus. The trial did not show a statistically significant separation between daxdilimab and placebo on the primary endpoint, which measured low SLE disease activity.

However, the company reported numerical differences in other endpoints and stated that there were no safety concerns. Horizon Therapeutics remains committed to assessing the full dataset. The company's daxdilimab trials in alopecia areata, discoid lupus erythematosus, and lupus nephritis are still ongoing.

Following the announcement, $HZNP declined by $1.18 (-1.17%) to $100.00 in after-hours trading on Friday.

 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)

Tags

Social Shares

Post Your Comments

Want To Find Some News?

Recent Posts

News By Industries

Tags